Interleukin Genetics Announces Completion of Interim Financing

   WALTHAM, Mass.--(BUSINESS WIRE)--Aug. 5, 2002--Interleukin
Genetics, Inc. (NASDAQ:ILGN) announced today that it has entered into
agreements with respect to interim financing in the form of a one-year
bridge loan. The company expects to close on commitments of $525,000,
which are in escrow, by the end of the week. With this funding,
Interleukin Genetics expects to be able to operate into October, 2002.
"This interim financing will allow us to continue both our basic
science research and our clinical studies," said Philip R. Reilly, the
company's Chairman and CEO. "Meanwhile, we are continuing discussions
with several large companies about the possibility of entering into a
strategic alliance.
   "The successful completion of this bridge loan was critically
important," acknowledged Reilly. "We expect to complete data analysis
on two of our three most important clinical research efforts by Q4,
2002. One study, based on a large, well characterized population that
has been followed for more than a decade through an NIH funded
program, is designed to refine our understanding of the risk of heart
disease in persons born with a common polymorphism of the IL-1 gene.
The other, research that we are conducting in cooperation with
scientists at Kaiser Permanente's Center for Health Research, assesses
the importance of a common polymorphism on the risk of heart attacks
in persons with adult onset diabetes. Since the company has recently
received a United States patent covering diagnostic testing in this
area, if either of the studies meet our endpoints, the data should
help draw needed capital."
   The securities being issued in the bridge financing will not be
registered under the Securities Act, and may not be sold nor may
offers to buy be accepted, in the absence of applicable exemption
from the registration requirements of the Securities Act. This press
release shall not constitute an offer to sell or the solicitation of
an offer to buy, nor shall there be any sale of the securities being
issued in the bridge financing in any state in which such offer,
solicitation or sale would be unlawful prior to their registration or
qualification under the securities laws of any such state.

   About Interleukin

   Interleukin Genetics is a biotechnology company focused on
inflammation. The company uses functional genomics to develop
diagnostic and therapeutic products based on the genetic variations in
people to help prevent or treat diseases of inflammation.
Interleukin's TARxGET (Translating Advanced Research in Genomics into
more Effective Therapeutics) programs focus on the areas of
cardiovascular disease, rheumatoid arthritis and osteoporosis and
include the development of tests to assess a person's risk for heart
disease and osteoporosis as well as a test to help doctors and
patients choose the best course of therapy for rheumatoid arthritis.
These products will enable the managed care industry to improve
patient care and better allocate resources. In addition to its
research partnerships with numerous academic centers in the U.S. and
Europe, Interleukin's corporate collaborators include the leading
healthcare organizations, Kaiser Permanente and UnitedHealth Group.
For more information about Interleukin and its ongoing programs,
please visit http://www.ilgenetics.com.

   Certain statements contained herein are "forward-looking"
statements including statements regarding the closing of the interim
financing, expectations about operating into October, the completion
of clinical research and data analysis, meeting our clinical studies'
endpoints, the entering into of a strategic alliance and the drawing
of capital (as such term is defined in the Private Securities
Litigation Reform Act of 1995). Because such statements include risks
and uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Factors that
could cause actual results to differ materially from those expressed
or implied by such forward-looking statements include, but are not
limited to, the company's ability to close on interim financing,
completing clinical research and data analysis, meeting expectations
about operating into October, meeting our clinical studies' endpoints,
completing a strategic alliance, risk of market acceptance of Company
products, ability of the Company to raise necessary capital, risk of
technology and products obsolescence, delays in development of
products, reliance on partners, competitive risks and those risks and
uncertainties described in the Company's Form 10-K as filed on March
28, 2002, and in other filings made by the Company with Securities and
Exchange Commission. The Company disclaims any obligation to update
these forward-looking statements.

    CONTACT: Interleukin Genetics, Inc.
             Sharon Leibowitz, 781/398-0700
             or
             MacDougall BioCommunications, Inc.
             Kari Lampka, 508/647-0209